The sickle cell hemolytic transfusion reaction syndrome

BACKGROUND: Patients with sickle cell anemia may develop serious, life‐ threatening hemolytic transfusion reactions (HTRs). More severe anemia may develop after the HTR than was present before transfusion, which suggests the possibility of an increased rate of hemolysis of autologous red cells. STUD...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 37; no. 4; pp. 382 - 392
Main Authors Petz, L. D., Calhoun, L., Shulman, I. A., Johnson, C., Herron, R. M.
Format Journal Article
LanguageEnglish
Published Edinburgh, UK Blackwell Science Ltd 01.04.1997
Blackwell Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND: Patients with sickle cell anemia may develop serious, life‐ threatening hemolytic transfusion reactions (HTRs). More severe anemia may develop after the HTR than was present before transfusion, which suggests the possibility of an increased rate of hemolysis of autologous red cells. STUDY DESIGN AND METHODS: The signs and symptoms occurring during eight severe HTRs that occurred in five patients with sickle cell anemia were reviewed, as were published reports by other investigators. Calculations of red cell production and destruction incorporating known correction factors for reticulocyte maturation were performed to determine the most probable mechanism for the striking drop in hematocrit observed in several instances. RESULTS: A characteristic constellation of findings was recognized in some severe HTRs in patients with sickle cell anemia. Calculations of daily red cell production and senescence indicated that a marked drop in hematocrit occurs when erythropoiesis is suppressed in a patient with a short red cell life span and that this could account for severe posttransfusion anemia when donor red cells are hemolyzed during an HTR. CONCLUSION: A sickle cell HTR syndrome was defined. A rapid increase in the severity of anemia occurs in patients with sickle cell anemia when all donor red cells are hemolyzed during an HTR and when there is suppression of erythropoiesis, as commonly occurs as a result of transfusion or concomitant illness. Although an increased rate of hemolysis of autologous red cells may also occur, more definitive data are required to document that in these patients.
Bibliography:ark:/67375/WNG-2CSMZJ58-0
istex:82C39B3420CD355C9B1BAE4DD7A9AA1C4359A33A
ArticleID:TRF3713
Loni Calhoun, MT(ASCP) SBB, Senior Technical Specialist, UCLA Medical Center.
Ira A. Shulman, MD, Director of Transfusion Medicine, University of Southern California, Los Angeles, CA.
Cage Johnson, MD, Department of Medicine, University of Southern California.
Ross M. Herron, MD, Medical Director, American Red Cross Blood Services, Southern California Region, Los Angeles, CA.
ObjectType-Case Study-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-2
ISSN:0041-1132
1537-2995
DOI:10.1046/j.1537-2995.1997.37497265338.x